Here are some of the standout moments from 2024 that drove our commitment to leadership in research, education, patient care, and innovation, all aimed at expanding knowledge and enhancing health worldwide.
The recognition of Krogan, Shoichet, Manglik, and Giacomini underscores the school’s commitment to fostering groundbreaking research that addresses critical issues in health care and pharmaceutical sciences.
The first program of its kind in the United States, the MS in AICD3 is enabling its graduates to gain a competitive edge for some of the most desirable jobs in the biopharmaceutical industry and in academia.
The Department of Bioengineering and Therapeutic Sciences (BTS) chair is leading a multidisciplinary team that will receive federal funding to prevent side effects before drugs go to clinical trials.
The director of the UCSF Institute for Human Genetics (IHG) is being recognized for his lab’s work investigating gene regulatory elements––their relationship to human diversity and disease and their utilization for gene therapy.
Bhushan Kharbikar, PhD, a postdoctoral fellow in the laboratories of Professors Qizhi Tang, PhD, and Tejal Desai, PhD, has been awarded a prestigious JDRF Advanced Postdoctoral Fellowship. JDRF is the leading global organization funding type 1 diabetes (T1D) research.
The Preclinical Design and Clinical Translation of TB Regimens (PReDicTR) Consortium has been awarded a $30.8M grant over five years to research the most effective treatment options for future clinical testing.
School researchers netted $36.7M from 65 grants, fueling efforts spanning drug discovery, bioengineering, pharmacokinetics, clinical pharmacy, and more.
The first program of its kind in the United States, the MS in AICD3 will enable its graduates to gain a competitive edge for some of the most desirable jobs in the biopharmaceutical industry and in academia.
